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Purpose: To identify, in the international staging database of the
International Association for the Study of Lung Cancer, those
prognostic factors that were significant and independent of clinical
stage.
Material and Methods: From the data submitted to the staging data
base concerning 100,869 patients, cases were selected for which all
the following variables were available: clinical stage, age, gender,
performance status (PS), and histologic cell types. For non-small
cell lung cancer (NSCLC), 12,428 patients were assessable, and for
SCLC, 6609 patients were available for this study. Methods used
were Cox regression analyses and recursive partitioning and amal-
gamation analyses.
Results: PS appeared to be a very important prognostic factor for
survival in addition to clinical stage. Age and gender were other
independent significant variables; For NSCLC and SCLC separately,
recursive partitioning and amalgamation allowed the identification
of four groups of patients with differing prognoses. In advanced
NSCLC (stage IIIB / IV), some routine laboratory tests (mainly white
blood cells and hypercalcaemia) were also found to be significant
prognostic variables. In SCLC, albumin was an independent biologic
prognostic factor.
Conclusion: In addition to stage, PS and, to a lesser extent, age and
gender seem to be important prognostic factors for survival in lung
cancer. Although this data was obtained from the largest series ever
used for such an analysis in lung cancer, these prognostic factors and
models require confirmation in the prospective study already planned
by the International Association for the Study of Lung Cancer Lung
Cancer Staging Project.
(J Thorac Oncol. 2008;3: 457–466)
The International Association for the Study of Lung Cancer(IASLC) International Staging Committee (ISC) has sub-
mitted proposals for revision of the tumor, node, metastasis
(TNM) descriptors1–4 and stage groupings5 for lung cancer in
the forthcoming (7th) edition of the International Union
Against Cancer and American Joint Committee on Cancer
TNM Classification of Malignant Tumors. The suggestions
are based on survival analyses that show better discrimination
is achieved by these changes to the TNM descriptors and
stage groupings. These proposals were developed using a
very large database that was specifically collected from indi-
vidual databases for that purpose.1 The prognostic factors
subcommittee of the ISC analyzed in the retrospective ISC
database the role of additional prognostic factors for survival,
whether related to the tumor or patient characteristics.
METHODS
We describe here the methods specifically used for the
purpose of the present study, which is the identification of
significant independent prognostic factors for survival in
addition to the anatomic extent of disease, expressed by
TNM. The general methodology of the IASLC Lung Cancer
Staging Project and the major proposals have already been
published.1–6
Population
The total number of patients submitted to the staging
data basis was 100,869 of whom 81,015 remained eligible for
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analysis after exclusion of cases outside the study period
(1990–2000), those with unknown cell type, those not newly
diagnosed at the point of entry and those with inadequate
information on stage, treatment or follow-up. Of the eligible
patients there were 67,725 cases of non-small cell lung cancer
(NSCLC) and 13,290 with SCLC.
Among the potentially useful prognostic variables for
lung cancer survival (Table 1), data for many were not available
in the IASLC staging project database, such as those related to
tumor biology or the role of fluorodeoxyglucose position emis-
sion tomography (FDG-PET) scanning. For this reason, we had
to restrict our analysis to those variables for which we had
enough information in a significant number of patients. These
included clinical stage, expressed as TNM for NSCLC and
limited disease (LD) versus extensive disease (ED) for SCLC
(defined by the local institution), age, gender, performance status
(PS), and histologic cell type. For NSCLC, 12,428 patients with
stage I–IV were assessable and for SCLC, 6609 (3739 with ED
and 2870 with LD). For smaller subsets of SCLC and advanced
stage NSCLC, we had laboratory values: serum calcium, serum
albumin, serum sodium, hemoglobin, and white blood cell count
(WBC).
Statistical Analysis
Survival was measured from the date of entry (date of
diagnosis for registries, date of registration for trials) for clinically
staged data and was calculated by the Kaplan-Meier method.
Prognostic groups were assessed by Cox regression analysis, using
the SAS system for windows version 9.0 PHREG procedure.
Recursive partitioning and amalgamation (RPA) anal-
yses were performed to generate tree-based models by stage
plus the key prognostic factors; age, gender, PS, and, for
NSCLC only, cell type. The analyses were performed on a
randomly selected training set comprising two-thirds of the
available cases, reserving the remaining cases for later vali-
dation. Separate training and validation sets were established
for NSCLC and SCLC. The random selection processes were
stratified by type of database submission (clinical trials,
registries, consortia/surgical series) and time period of case
entry (1990–1995 versus 1995–2000).
The RPA analysis generated tree-based models for the
survival data using logrank test statistics for recursive partition-
ing, for selection of the important groupings and bootstrap
resampling to correct for the adaptive nature of the splitting
algorithm. The terminal nodes were then grouped according to
similar hazards and the newly formed groups were in each case
evaluated using the remaining one-third of the data.
Laboratory values were first checked for consistency of
the units used by laboratories across the contributing data-
bases, and queries or corrections were made where necessary.
When viewing survival prognosis for each laboratory mea-
sure as a continuous variable in a running logrank test, we
found that the best split point for the data for prognosis was
consistently at the defined upper or lower limits of normal.
Therefore each result was defined dichotomously based on
the known normal range for each laboratory measurement.
Using these cutpoints, the laboratory measurements were
analyzed for prognosis univariately using Kaplan Meier, and
multivariately in conjunction with other factors with Cox
proportional hazards regression.
Because of the multiple tests performed on the data-
base, the level of significance for p was chosen as 0.01.
RESULTS
Non-small Cell Lung Cancer
Analyses of Survival Using General Characteristics
Cox Models
The following variables were considered: clinical TNM
stage as proposed by the IASLC Lung Cancer Project, age,
gender, histologic cell type (adenocarcinoma versus squamous
cell carcinoma versus other types), and performance status (PS)
using the Zubrod scale.7 The results of the Cox proportional
hazards regression model performed on the whole population
(12,426 patients) is shown in Table 2. Older age, more advanced
stage, male gender, poorer PS and nonsquamous cell histology
were found to be significantly associated with decreased sur-
vival. The R2 value for the full model with clinical stage (as
proposed by IASLC) and the full set of prognostic factors is
36.2. For a model with just clinical stage and without the other
factors, the R2 value is 32.9. Thus, removing the prognostic
factors from the model does not substantially effect the hazard
ratios on the clinical stage parameters.
The same prognostic factors were found to be important
when the multivariate analysis was performed using the 6th
edition of the TNM Classification of Malignant Tumors8,9 to
determine clinical stage (Table 3).
When prognostic factors were analyzed by clinical stage,
as proposed by the IASLC staging project (Table 4), histology
cell type was a significant prognostic factor for survival only in
patients with stage IIIA, whereas PS, gender, and age were
significant in all stages, but with a lower limit for age in
advanced stages.
TABLE 1. Potentially Useful Prognostic Variables for Lung Cancer Survival
Tumor characteristics: localization of metastatic sites: brain, liver, adrenals, bone, lung; number of metastatic sites; pleural effusion; type of lesions
(assessable, measurable); tumor size and volume; histology: non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); squamous cell
carcinoma versus adenocarcinoma versus large cell carcinoma . . .; neuroendocrine tumors; tumor differentiation and grade; lymphatic and blood vessel
invasion; symptoms; fluorodeoxyglucose positron emission tomography (FDG-PET) scan findings
Patients characteristics: age; gender; performance status (PS); weight loss; smoking history; race; comorbidities (Charslon’s index, Colinet’s simplified
comorbidity score)
Laboratory parameters: serum bilirubin; serum calcium; serum sodium; serum creatinine; hemoglobinemia; leucocytosis; neutrophilia; platelets; serum
alkaline phosphatases; sGOT; sGPT; serum albumin; serum CEA; serum LDH; serum NSE; serum CYFRA
Tumor biology: individual markers (p53; bcl-2; microvascular density; VEGF; EGFR; c-erbB-2; Ki-67; Ras; COX2; TTF1; aneuploidy), genetic signatures
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RPA Analysis
A recursive positioning and amalgamation analysis was
performed on the patient population, randomly divided for
that purpose in to a learning set (66%  8199 cases) and a
validation set (34%  4227 cases). The following factors
were used to obtain the tree shown in Figure 1: PS (ordered),
IASLC stage (ordered with IIIB-IV combined), age (contin-
uous), squamous cell type (yes/no), and gender. The result-
ing, pruned survival tree showed significant split points for
stage, age and PS; cell type did not appear as important as
those variables. The numbers at the terminal nodes (Figure 1)
represent the parameter estimates (log-hazard ratio) and the
number of cases for each terminal node group. The reference
group with best prognosis is circled in blue at the far left of
the figure. The colored circles encompass those groups with
similar prognoses. Four groups with significantly different
prognosis were identified: Group 1 (blue) with stage IA–IIA
(any age and any PS); Group 2 (red) with stage IIB/IIIA and
PS 0–1 (any age); Group 3 (green) with stage IIB/IIIA and PS
2 (any age) or with stage IIIB/IV and PS 0 (any age) or with
stage IIIB/IV, age 81 years and PS 1; Group 4 (orange)
with stage IIB/IIIA and PS 3–4 (any age) or with stage
IIIB/IV and PS 2–4 (any age) or with stage IIIB/IV, PS 1 and
age 80 years. The resulting amalgamated categories were
applied to a survival analysis on the validation set of patients
(Figure 2). Median survival times were, respectively, 53 months
for group 1, 16 months for group 2, 8 months for group 3, and
3 months for group 4.
Analyses of Survival Using Laboratory Values in
Advanced Stage IIIB/IV
A total of 7280 cases with advanced NSCLC in the
database had data on at least one of the following laboratory
values in addition to the other prognostic factors (age, gender,
PS): calcium (1316 cases), albumin (1887 cases), sodium (1708
cases), hemoglobin (1564 cases), andWBC (2126 cases). A Cox
model was performed with each individual laboratory value and
the other prognostic factors (Table 5). The laboratory variables
in advanced NSCLC seemed to be strong prognostic factors in a
magnitude similar to PS, whereas age and gender were weaker.
In 537 patients, data was available on all of the five laboratory
values. A multivariate model (Table 6) identified as strong
significant prognostic factors (p  0.001) PS and WBC, fol-
lowed by calcium (p  0.0077), albumin (p  0.013), and age
75 years (p  0.0415).
TABLE 2. Multivariate Analysis of Prognostic Factors for
Survival in NSCLC, Using General Characteristic Variables
(Clinical TNM Stage as Proposed by IASLC Staging Project,
Age, Gender, PS, Histological Cell Type)
Variable n/N (%) HR (95% CI) P
Stage II 1531/12426 (12%) 1.80 (1.65, 1.97) 0.001
Stage IIIA 2048/12426 (16%) 2.71 (2.49, 2.95) 0.001
Stage IIIB/IV 7280/12426 (59%) 5.34 (4.95, 5.76) 0.001
Age (continuous) N  12426 1.01 (1.00, 1.01) 0.001
Squamous cell type 5304/12426 (43%) 0.93 (0.89, 0.97) 0.001
Male gender 9764/12426 (79%) 1.17 (1.11, 1.23) 0.001
PS 1 (vs.0) 6294/12426 (51%) 1.38 (1.32, 1.44) 0.001
PS 2 (vs. 0) 1423/12426 (11%) 2.09 (1.95, 2.23) 0.001
PS 3–4 (vs. 0) 579/12426 (5%) 3.48 (3.17, 3.83) 0.001
R2  36.2%.
NSCLC, non-small cell lung cancer; IASLC, International Association for the
Study of Lung Cancer; TNM, tumor, node, metastasis; PS, performance status; HR,
hazard ratio; 95% CI, 95% confidence interval; p value from Wald 2 Test in Cox
Regression; R2: R-squared using method by O’Quigley and Xu.
TABLE 3. Multivariate Analysis of Prognostic Factors for Survival
in NSCLC, Using the 6th Edition of TNM (R2  35.4%)
Variable n/N (%) HR (95% CI) P
Age N  12426 1.01 (1.01, 1.01) 0.001
6th Ed TNM II 1119/12426 (9%) 1.86 (1.70, 2.03) 0.001
6th Ed TNM IIIA 1925/12426 (15%) 2.54 (2.35, 2.75) 0.001
6th Ed TNM IIIB & IV 7401/12426 (60%) 4.79 (4.48, 5.12) 0.001
Male 9764/12426 (79%) 1.16 (1.11, 1.22) 0.001
PS 1 6294/12426 (51%) 1.38 (1.32, 1.45) 0.001
PS 2 1423/12426 (11%) 2.11 (1.97, 2.25) 0.001
PS 3–4 579/12426 (5%) 3.50 (3.18, 3.85) 0.001
Squamous cell 5304/12426 (43%) 0.92 (0.88, 0.96) 0.001
NSCLC, non-small cell lung cancer; TNM, tumor, node, metastasis; PS, perfor-
mance status; HR, hazard ratio; 95% CI, 95% confidence interval; p value from Wald
2 Test in Cox Regression; R2: R-squared using method by O’Quigley and Xu.
TABLE 4. Multivariate Analysis of Prognostic Factors for
Survival Within Clinical Stages in NSCLC (as proposed by the
IASLC for the 7th Ed of TNM), Using General Characteristic
Variables (Age, Gender, PS, Histological Cell Type)
Variable n/N (%) HR (95% CI) P
Stage I–II
Male 2628/3098 (85%) 1.22 (1.06, 1.40) 0.006
Squamous 1747/3098 (56%) 0.99 (0.90, 1.09) 0.840
Age N  3098 1.02 (1.01, 1.02) 0.001
PS 1 1852/3098 (60%) 1.32 (1.19, 1.46) 0.001
PS 2 117/3098 (4%) 2.60 (2.07, 3.27) 0.001
PS 3–4 25/3098 (1%) 7.19 (4.64, 11.14) 0.001
Stage IIIA
Age N  2048 1.01 (1.00, 1.01) 0.002
Male 1635/2048 (80%) 1.21 (1.07, 1.38) 0.003
Squamous 1072/2048 (52%) 0.86 (0.78, 0.95) 0.003
PS 1 871/2048 (43%) 1.33 (1.20, 1.48) 0.001
PS 2 155/2048 (8%) 1.93 (1.60, 2.33) 0.001
PS 3–4 37/2048 (2%) 3.94 (2.74, 5.69) 0.001
Stage IIIB/IV
Age N  7280 1.00 (1.00, 1.01) 0.011
Squamous 2485/7280 (34%) 0.95 (0.90, 1.00) 0.042
Male 5501/7280 (76%) 1.15 (1.09, 1.22) 0.001
PS 1 3571/7280 (49%) 1.41 (1.34, 1.50) 0.001
PS 2 1151/7280 (16%) 2.13 (1.97, 2.30) 0.001
PS 3–4 517/7280 (7%) 3.45 (3.11, 3.83) 0.001
NSCLC, non-small cell lung cancer; IASLC, International Association for the
Study of Lung Cancer; TNM, tumor, node, metastasis; PS, performance status; HR,
hazard ratio; 95% CI, 95% confidence interval; p value from Wald 2 Test in Cox
Regression.
Journal of Thoracic Oncology • Volume 3, Number 5, May 2008 TNM Classification of Malignant Tumors
Copyright © 2008 by the International Association for the Study of Lung Cancer 459
Small Cell Lung Cancer
Analyses of Survival Using General Characteristics
Cox Models
The IASLC database contained data for analysis of
prognostic factors for 6609 cases with SCLC. This in-
cluded 2870 patients with LD and 3739 with ED. For each
individual, data was available on PS, age, and gender. Two
percent (122 cases) had had surgery. Table 7 shows the
results of the multivariate analysis for survival on the
whole population. All variables tested (PS, extent of disease,
gender, and age) were found to be independent prognostic
FIGURE 1. Survival tree of the recursive par-
titioning and amalgamation analysis, per-
formed on a learning set of 8199 non-small
cell lung cancer cases.
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FIGURE 2. Survival obtained for the amal-
gamated groups in the validation set of 4227
non-small cell lung cancer patients.
TABLE 5. Analyses Using Laboratory Values in Advanced NSCLC Disease (Stages IIIB/IV): Results of Models with Individual
Laboratory Variables
Laboratory Variable No. of Cases
Age >75 yr Gender: Male PS (ordered)
Laboratory
Variable
p HR P HR P HR P HR
Calcium 10.4 mg/dl 1316 0.2248 1.19 0.0356 1.16 0.0001 1.35 0.0010 1.55
Albumin 3.2 g/dl 1887 0.0116 1.28 0.1875 1.07 0.0001 1.47 0.0001 1.45
Sodium 135 mmol/l 1708 0.0674 1.27 0.0016 1.21 0.0001 1.35 0.0001 1.35
WBC 10,000 cells/ml 2126 0.0006 1.50 0.0277 1.13 0.0001 1.42 0.0001 1.43
Hemoglobin 12 g/dl for females,
13 g/dl for males
1564 0.0725 1.26 0.1746 1.09 0.0001 1.34 0.0003 1.21
NSCLC, non-small cell lung cancer; PS, performance status; WBC, white blood cells.
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factors for survival. Table 8 shows the results of the models
performed on the subsets of patients with limited or ED. The
same independent prognostic factors (PS, gender, and age) were
identified as in NSCLC.
RPA Analyses
For the RPA analysis, the population was split in to a
learning set (66% of the cases  4359) and a validation set
(34%  2250). The factors entered in to this analysis were:
stage (LD versus ED), PS (0–4) age and gender. The result-
ant tree (Figure 3) shows that stage and PS are the two most
important prognostic factors. The reference group with best
prognosis is circled in blue at the far left of the figure. Four
groups with differing prognoses were identified: group 1
(blue) with LD, PS 0 and age 60 years or LD, PS 1–2 and
age65 years; group 2 (red) with LD, PS 1–2, age65 years
or female with ED, PS 0, and age 65 years; group 3 (green)
female with ED, PS0 and age65 years or male with ED, PS
0 or both genders with ED, PS 1, age 70 years; and group
4 (orange) with LD PS 3–4 or with ED, PS 1, age 70 years
or with ED, PS 2–4. The resulting amalgamated categories
were applied to a survival analysis in the validation set
(Figure 4). Median survival times were, respectively, 17 months
for group 1, 12 months for group 2, 10 months for group 3, and
6 months for group 4.
Analyses of Survival Using Laboratory Values
A total of 6609 cases with SCLC in the database had data
on at least one of the following laboratory values in addition to
the other prognostic factors (stage, age, gender, PS): calcium
(1849 cases), albumin (2773 cases), sodium (2390 cases), he-
moglobin (1487 cases), and WBC (1828 cases). A Cox model
was performed with each individual laboratory value and the
other prognostic factors (Table 9). Two laboratory variables
(sodium and albumin) appeared to be very significant prognostic
factors in addition to stage, PS, and gender. In 650 patients there
was data available on all five laboratory values. A multivariate
model (Table 10) identified albumin only, in addition to extent
of disease and gender, as significant prognostic factors.
DISCUSSION
The IASLC staging project allowed an analysis of
prognostic factors for survival in a very large population of
lung cancer patients: more than 12,000 with NSCLC and
more than 6000 with SCLC. In addition to clinical stage, PS
appeared to be a very important prognostic factor. Age and
gender were other independent significant variables. For
NSCLC, histologic cell type was a significant prognostic
factor in stage IIIA, with squamous cell lung cancer having a
better prognosis in comparison to other cell types. For both
NSCLC and SCLC, RPA allowed the identification of four
groups of patients with differing prognoses. Finally, in ad-
vanced NSCLC, some biologic variables (serum calcium,
albumin, and WBC) were found to be prognostic factors in
addition to stage, age, and gender. In SCLC, albumin only, in
addition to extent of disease and gender, was identified as a
significant prognostic biologic factor. Our findings are sum-
marized in Table 11 with a grading as following: and
  factors present in any model;   factors signif-
icant in RPA and Cox models; factors significant in Cox
models (or in a meta-analysis for SUVmax); §  biologic
factors significant in Cox models not taking into consider-
ation other biologic variables.
TABLE 6. Multivariate Model for Survival Performed in
Advanced NSCLC (Stages IIIB/IV) in a Set of 537 Patients for
which all 5 Laboratory Variables were Available
Variable P HR
Age 75 yr 0.0415 1.39
Male 0.4761 0.93
PS (ordered: 0, 1, 2, 3–4) 0.0001 1.44
Calcium 10.4 mg/dl 0.0077 1.77
Albumin 32 g /dl 0.013 1.33
Sodium 135 mmol/l 0.4823 1.09
Hemoglobin 12 g/dl for females, 13 g/dl
for males
0.1235 1.16
WBC 10,000 cells/l 0.0001 1.60
NSCLC, non-small cell lung cancer; PS, performance status; WBC, white blood
cells; HR, hazard ratio.
TABLE 7. Multivariate Analysis of Prognostic Factors for
Survival in SCLC, Using General Characteristic Variables
(Limited vs. Extensive Stage, Age, Gender, PS)
Variable n/N (%) HR (95% CI) P
Age N  6609 1.01 (1.01, 1.02) 0.001
Extensive stage
(vs Lim.)
3739/6609 (57%) 2.13 (2.02, 2.25) 0.001
Male (vs. female) 4368/6609 (66%) 1.25 (1.19, 1.32) 0.001
PS 1 3161/6609 (48%) 1.36 (1.28, 1.44) 0.001
PS 2 1060/6609 (16%) 1.93 (1.78, 2.09) 0.001
PS 3–4 349/6609 (5%) 3.45 (3.05, 3.89) 0.001
SCLC, small cell lung cancer; PS, performance status; HR, hazard ratio; 95% CI,
95% confidence interval; p value from Wald 2 Test in Cox Regression.
TABLE 8. Multivariate Analyses of Prognostic Factors for
Survival in Limited and Extensive SCLC, Using General
Characteristic Variables (Age, Gender, PS)
Variable n/N (%) HR (95% CI) P
Limited stage
Age N  2870 1.01 (1.01, 1.02) 0.001
Male 1838/2870 (64%) 1.21 (1.11, 1.32) 0.001
PS 1 1338/2870 (47%) 1.42 (1.30, 1.55) 0.001
PS 2 277/2870 (10%) 1.72 (1.49, 1.98) 0.001
PS 3–4 129/2870 (4%) 3.68 (3.03, 4.47) 0.001
Extensive stage
Age N  3739 1.01 (1.01, 1.02) 0.001
Male 2530/3739 (68%) 1.28 (1.20, 1.38) 0.001
PS 1 1823/3739 (49%) 1.32 (1.21, 1.43) 0.001
PS 2 783/3739 (21%) 1.98 (1.79, 2.18) 0.001
PS 3–4 220/3739 (6%) 3.32 (2.84, 3.88) 0.001
SCLC, small cell lung cancer; PS, performance status; HR, hazard ratio; 95%
CI, 95% confidence interval; p value from Wald 2 Test in Cox Regression.
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There are some methodological problems that may
limit the generalization of these results. Firstly, the retrospec-
tive nature of the database, that allowed such a very high
number of lung cancer patients to be collected, inevitably
lead to a lot of missing data on some prognostic factors. This
restricted our analysis to a subset of the population for which
we had each prognostic factor: clinical stage as proposed by
the IASLC staging project,1 PS, gender, age, and histologic
cell type. Pathologically, stage was not considered because in
general we did not get much prognostic factor data, particular
FIGURE 3. Survival tree of the recursive parti-
tioning and amalgamation analysis, performed
on a learning set of 4359 small cell lung can-
cer cases.
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FIGURE 4. Survival obtained for the amal-
gamated groups in the validation set of 2250
small cell lung cancer patients.
TABLE 9. Analyses Using Laboratory Values in SCLC: Results of Models with Individual Laboratory Variables
Laboratory Variable No. of Cases
Stage: Extensive Age >75 yr Gender: Male PS (ordered)
Laboratory
Variable
P HR P HR P HR P HR P HR
Calcium 10.4 mg/dl 1849 0.0001 1.87 0.8528 1.02 0.0008 1.19 0.0001 1.5 0.0608 1.28
Albumin 3.2 g/dl 1887 0.0001 1.79 0.0403 1.21 0.0001 1.23 0.0001 1.44 0.0001 1.31
Sodium 135 mmol/l 2390 0.0001 1.96 0.6003 1.07 0.0001 1.19 0.0001 1.48 0.0001 1.31
WBC 10,000 cells/l 1828 0.0001 2.12 0.8544 1.03 0.001 1.26 0.0001 1.33 0.2414 1.07
Hemoglobin 12 g/dl for females,
13 g/dl for males
1487 0.0001 2.25 0.9618 0.99 0.0011 1.21 0.0001 1.34 0.5040 1.04
SCLC, small cell lung cancer; PS, performance status; HR, hazard ratio; WBC, white blood cells.
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PS, from the surgical database and for those for which we had
the data, they are nearly all either P.S. 0 or 1, which is not
very interesting for prognostic analysis. For SCLC, we were
unable to use TNM stage and limited our analysis to that
limited versus ED as defined in the local databases. As biologic
variables were mainly available in patients with advanced
NSCLC (stage IIIB/IV), the analysis was restricted to those
cases for which we also had the other prognostic factors (age,
PS, gender). When we wished to study, in a multivariate model,
the five biologic variables, data was only available in little more
than 500 patients. Secondly, the local databases amalgamated in
the staging project were of differing types: clinical trials, surgical
series, institution series and registries. Some have been the topic
of prognostic analyses that have already been published. There-
fore our results are not fully independent of the data already in
the literature. Thirdly, the effect of the treatment has not been
taken into account because of the great heterogeneity of the
various local databases. The prognostic analysis thus reflects not
only the natural history of the disease but also the modalities of
treatment used according to the local attitudes worldwide.
Fourthly, a large number of statistical tests necessitated an
increase of the threshold level of significance. Our analysis does
not have the strength of a prospective study in which statistical
analysis could be based upon a predefined primary end point.
For all of these reasons the reported conclusions have to be
considered as exploratory, requiring confirmation in a prospec-
tive validation study.
Despite these limitations, this study of prognostic fac-
tors provides important information. It confirms, in the largest
series ever published, the prognostic role of gender and age in
addition to PS and clinical stage, whether one uses the 6th
edition of the TNM Classification of Malignant Tumors or the
IASLC proposals for the forthcoming 7th edition.
Similar general prognostic factors were found to be im-
portant for NSCLC and SCLC. The RPA allowed the construc-
tion of trees (Figures 1 and 3), which may help in the manage-
ment of lung cancer patients. For NSCLC, the model developed
included all clinical stages, which is a new finding. Indeed the
published survival models have so far been limited to retrospec-
tive analyses of data bases of clinical trials performed by
cooperative groups in advanced disease.10–13 It should be noted
that the number of patients included in those studies ranged form
893 to 2631, which is far less than the 12,428 cases available for
our analyses. By taking into consideration the clinical stage in a
population with a much broader case-mix, stage seems to be the
strongest prognostic factor. PS becomes important only in stage
IIB or higher when analyzed with RPA due to the very low
frequency of patients with poor PS in the early stage cases
(Figures 1 and 2).
For SCLC, we also identified that the extent of disease at
presentation, classified as ED versus LD, was the most important
factor, with PS and age also being important. Gender was found
to have a role in deciding prognosis in ED (Figures 3 and 4).
Other models, performed on databases of clinical trial cases
from cooperative groups, are published in the literature.14–16
These publications also identify the extent of disease at presen-
tation as the main factor. The number of patients included in
those analyses was respectively, 614, 2580, and 763, many
fewer than those used in the present study. The large size of our
series allowed us to perform a validation analysis in a subset of
2250 patients, which were not used to construct the model.
Other prognostic factors were identified in this study by
the analysis of data within different stages of disease. Histologic
cell type is a controversial prognostic factor in NSCLC.17 The
data presented in this report (Table 4) revealed that cell type was
only a significant prognostic factor for survival in stage IIIA in
addition to PS, age and gender, when stage IIIA was defined
using the IASLC proposals for the 7th edition of TNM.5 Squa-
mous cell cancer seemed to have a better prognosis than other
histologies. This information suggests one should stratify by
histology in trials that include patients with stage IIIA disease.
TABLE 10. Multivariate Model for Survival Performed in
SCLC in a set of 650 Patients for which the 5 Laboratory
Variables were Available
Variable P HR
Stage: ED 0.0001 1.931
Age 75 yr 0.4064 1.146
Male 0.0007 1.336
PS (ordered: 0, 1, 2, 3–4) 0.0001 1.283
Calcium 10.4 mg/dl 0.9451 1.019
Albumin 32 g/dl 0.0168 1.385
Sodium 135 mmol/l 0.0483 1.221
Hemoglobin 12 g/dl for females, 13 g/dl
for males
0.0579 0.833
WBC 10,000 cells/l 0.7929 1.024
SCLC, small cell lung cancer; ED, extensive disease; PS, performance status;
WBC, white blood cells.
TABLE 11. Summary of the Prognostic Factors with a
Grading as Following:  and   factors present
in any model;   factors significant in RPA and Cox
models;   factors significant in Cox models (or in a
meta-analysis for SUVmax); §  biological factors
significant in Cox models not taking into consideration other
biological variables
Variable NSCLC SCLC
Clinical extent of diseasea  
Performance statusb  (IIB only) 
Age  (IIIB only) 
Male gender  
Squamous cell type  (IIIA only) N/A
PET SUVmax  N/A
Calcium c —
Albumin c 
Sodium §c §
White blood cells c —
Hemoglobin §c —
RPA, recursive partitioning and amalgamation; SUVmax, standard uptake value
maximum; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PET,
position emission tomography; TNM, tumor, node, metastasis; LD, limited disease; ED,
extensive disease; N/A, not applicable/not available.
a Extent of disease by TNM stage for NSCLC and LD/ED for SCLC.
b Performance status by Zubrod scale.
c Advanced stage IIIB/IV for NSCLC.
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Routine laboratory variables have been included in many
models for advanced disease published in the literature. Because
of a lot of missing data, the analysis of these was restricted to
assessing their value in advanced (stage IIIB/IV) NSCLC. Ad-
equate data was available on five blood tests: calcium, albumin,
sodium,WBC, and hemoglobin. All were found to be significant
variables (Table 5). A model with a small number of patients
was constructed, which suggested that WBC and calcium might
be important prognostic factors, in accordance with other stud-
ies.11,12,18 The same approach in SCLC allowed identifying
albumin as a significant independent factor in addition to PS and
extent, which is a new information, albumin having not been so
far investigated in large series.19
Many potentially useful prognostic variables (Table 1)
were not investigated because of missing data or missing
variables, inevitable in a retrospective database. Some could
not be assessed because they had only recently been sug-
gested, such as for those related to molecular biology or to the
value of PET scanning. In regard to the role of molecular or
biologic markers in lung cancer, more than 5000 articles have
been published, often of varying methodological quality. The
best evidence available in the literature at present on this
subject has come from the meta-analyses summarized in Table
12. The estimate of the prognostic value of these variables
reported in these studies is limited by their use of univariate
analyses. The independent role of the prognostic factors identi-
fied in this study has to be confirmed in prospective studies,
using methodology such as that recently proposed by Zhu et al.20
and the international recommendations REMARK.21 The prog-
nostic value of the primary tumor SUV max (maximal standard
uptake value) measured on FDG-PET has been assessed by a
meta-analysis of the literature, undertaken by the European Lung
Cancer Working Party evidence-based medicine committee for
the IASLC staging project. This showed that SUV max is a
strong prognostic factor for survival in a univariate analysis.22
This should be confirmed by a meta-analysis based on individual
patient data allowing multivariate analysis to be performed
which takes into account the prognostic factors identified in the
present article.
In conclusion, the present analysis of the database of
the IASLC staging project identified important prognostic fac-
tors for survival in lung cancer patients in addition to clinical
stage. Those factors were PS, age, and gender. In stage IIIA
NSCLC, histologic cell type seemed to be important. In ad-
vanced NSCLC some routine laboratory tests were found to be
additional, significant factors. In SCLC, albumin was also found
to be an independent prognostic factor. Models were constructed
using a RPA method for both NSCLC and SCLC. They allowed
the identification of groups of patients with differing prognoses,
taking into account clinical stage and PS and, to a lesser extent,
age, and gender. Although the results reported in this study were
obtained in the largest series ever used for prognostic analysis in
lung cancer, the prognostic variables and models found require
to be confirmed by a prospective study, such as that already
planned by the IASLC Lung Cancer Staging Project. It is our
hope that colleagues around the world will continue to support
this initiative.
APPENDIX 1
IASLC ISC
P. Goldstraw (Chairperson), Royal Brompton Hospital,
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Biostatistics, Seattle, Washington, USA; T. Le Chevalier (re-
signed), Institute Gustave Roussy, Villejuif, France; J. Crowley,
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Rusch, Memorial Sloan-Kettering Cancer Center, New York,
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Shaikh, Royal Brompton Hospital, London, UK; F.A. Shepherd,
University of Toronto, Toronto, Ontario, Canada; Y. Shimosato
TABLE 12. Meta-Analyses Published on the Prognostic
Value of Biological or Genetic Markers for Survival in Lung
Cancer
Biological
Variable
Prognostic
Factor Reference
Bcl-2 Good Martin et al., 200323
TTF1 Poor Berghmans et al., 200624
Cox2 Poor Mascaux et al., 200625
EGFR Poor Nakamura et al., 200626; Meert et al.,
200227
ras Poor Mascaux et al., 200528; Huncharek
et al., 199929
Ki67 Poor Martin et al., 200430
HER2 Poor Meert et al., 200331
Nakamura et al., 200532
VEGF Poor Delmotte et al., 200233
Microvascular
density
Poor Meert et al., 200234
p53 Poor Steels et al., 200135
Mitsudomi et al., 200036
Huncharek et al., 200037
Aneuploidy Poor Choma et al., 200138
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and P. K. Allen, MD Anderson Cancer Center- Radiation Ther-
apy (MDACC-RT), Houston, Texas, USA; J.P. Sculier and M.
Paesmans, European Lung Cancer Working Party (ELCWP);
Y.L. Wu, Guangdong Provincial People’s Hospital, Peoples
Republic of China; M. Pesek and H. Krosnarova, Faculty Hos-
pital Plzen, Czech Republic; T. Le Chevalier and A. Dunant,
International Adjuvant Lung Cancer Trial (IALT), France; B.
McCaughan and C. Kennedy, University of Sydney, Sydney,
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tikova, John Hopkins University, USA; J. Vansteenkiste, Leu-
ven Lung Cancer Group (LLCG), Belgium; C. Brambilla and
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try, France; J. Hunt and A. Park, Western Hospital, Melbourne
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tre of Serbia, Belgrade, Serbia; R. Rosell and V. Aberola,
Spanish Lung Cancer Group (SLCG), Spain; A.A. Vaporciyan
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